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Background: Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk
disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will
eventually cease to respond, while others will be resistant to growth factor therapy. Eventually, all lower-risk MDS
patients require multiple transfusions and long-term therapy. While some patients may respond briefly to
hypomethylating agents or lenalidomide, the majority will not, and new therapeutic options are needed for these
lower-risk patients. Our previous clinical trials with ezatiostat (ezatiostat hydrochloride, Telentra®, TLK199), a
glutathione S-transferase P1-1 inhibitor in clinical development for the treatment of low- to intermediate-risk MDS,
have shown significant clinical activity, including multilineage responses as well as durable red-blood-cell
transfusion independence. It would be of significant clinical benefit to be able to identify patients most likely to
respond to ezatiostat before therapy is initiated. We have previously shown that by using gene expression profiling
and grouping by response, it is possible to construct a predictive score that indicates the likelihood that patients
without deletion 5q will respond to lenalidomide. The success of that study was based in part on the fact that the
profile for response was linked to the biology of the disease.
Methods: RNA was available on 30 patients enrolled in the trial and analyzed for gene expression on the Illumina
HT12v4 whole genome array according to the manufacturer’s protocol. Gene marker analysis was performed. The
selection of genes associated with the responders (R) vs. non-responders (NR) phenotype was obtained using a
normalized and rescaled mutual information score (NMI).
Conclusions: We have shown that an ezatiostat response profile contains two miRNAs that regulate expression of
genes known to be implicated in MDS disease pathology. Remarkably, pathway analysis of the response profile
revealed that the genes comprising the jun-N-terminal kinase/c-Jun molecular pathway, which is known to be
activated by ezatiostat, are under-expressed in patients who respond and over-expressed in patients who were
non-responders to the drug, suggesting that both the biology of the disease and the molecular mechanism of
action of the drug are positively correlated.Background
Myelodysplastic syndrome (MDS) is a clonal stem cell dis-
order resulting in bone marrow failure and variable cytope-
nias. Development of new treatment strategies has greatly
improved the outlook for patients with MDS. There are
three FDA-approved drugs for therapy of patients who
have become transfusion-dependent, including two hypo-
methylating drugs (HMAs), azacitidine and decitabine,* Correspondence: ng2368@columbia.edu
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reproduction in any medium, provided the orand the thalidomide derivative lenalidomide. Patients
with higher-risk disease have been shown to benefit from
HMA therapy [1,2], while patients with lower-risk disease
with a karyotype of clonally restricted deletion of the long
arm of chromosome 5 (deletion 5q or del[5q]) are highly
responsive to lenalidomide [3,4]. Only 26% of transfusion-
dependent lower-risk patients without del(5q) will also
become transfusion-independent while on treatment [5],
but the FDA has not approved lenalidomide for these
patients. There are few treatment options for the major-
ity of transfusion-dependent MDS patients with lower-
risk disease. This situation represents a significant
unmet medical need. Once disease-modifying therapy isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physician to decide which drug will best benefit the indi-
vidual patient, as only a subset responds to any given
agent.
Ezatiostat (ezatiostat hydrochloride, TelintraW, TLK199),
a glutathione analog inhibitor of the enzyme glutathione
S-transferase P1-1 (GSTP1-1), causes dissociation of the
enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN)
complex, leading to JNK activation by phosphorylation.
Activated JNK phosphorylates c-JUN, which ultimately
results in the stimulation of all myeloid lineages hemato
poietic progenitor’s proliferation and maturation. In
addition, subsequent activation of the caspase-dependent
apoptotic pathway increases reactive oxygen species in
human leukemia blast cells. This cascade can trigger
apoptosis. In other words, the therapeutic action of eza-
tiostat appears to include both proliferation of normal
myeloid progenitors as well as apoptosis of the malig-
nant clone.
Our previous phase 2 study of ezatiostat demonstrated
that this drug can elicit a therapeutic response in a pro-
portion of patients with lower-risk MDS [6]. Trilineage
responses were observed in 4 of 16 patients (25%) with
trilineage cytopenia. Hematologic Improvement-Erythroid
(HI-E) was observed in 9 of 38 patients (24%), HI-
Neutrophil (HI-N) in 11 of 26 patients (42%), and HI-
Platelet (HI-P) in 12 of 24 patients (50%). In a subgroup
of 9 patients who were red-blood-cell (RBC)-transfusion-
dependent and HMA-naïve, a 47% HI-E rate was observed.
Three (16%) of these patients achieved complete RBC-
transfusion independence, and 3 of 9 (33%) reported multi-
lineage responses. While the responses seen in the lower-
risk patients resulted in hematologic improvement with
clinically significant reductions in RBC-transfusion require-
ments, and in some cases transfusion-independence, it is
clear that in this heterogeneous disease it would be advanta-
geous if a diagnostic predictor of response could be devel-
oped to optimize treatment outcomes.
Gene expression profiling studies can define signatures
that are capable of improving existing classification and
prognosis of multiple diseases, especially malignancies
which tend to be heterogeneous or of unknown or uncer-
tain origin. MDS is a group of hematopoietic stem cell dis-
orders that pose a unique challenge for gene expression
profiling by virtue of their inherent heterogeneity. How-
ever, we have previously shown that profiling can generate
distinct expression signatures based on the uniform group-
ing of patient response to a specific drug therapy [7]. In
an attempt to identify the subset of lower-risk patients
likely to benefit from therapy with ezatiostat, we exam-
ined pre-therapy marrow cells from ezatiostat-treated
MDS patients by gene expression profiling in order to
identify signatures which differentiate responders from
non-responders.Methods
Patient samples
A separate research protocol was submitted to the in-
stitutional review boards (IRBs) at the University of
Massachusetts Memorial Medical Center, Worcester, MA,
and at Saint Vincent’s Comprehensive Cancer Center,
New York, NY, seeking permission to perform the micro-
array analysis as described below. Once the research proto-
col was approved by the respective IRBs and informed
consent was obtained from each patient, samples from
lower-risk MDS patients treated with ezatiostat in the
phase 2 clinical trial at those institutions were obtained.
Mononuclear cells from pre-therapy bone marrow aspi-
rates were stored in Trizol at °C.
All patients had low- or intermediate-1-risk MDS as
determined by the International Prognostic Scoring System
(IPSS) and had not received growth factors for 4 weeks
prior to study enrollment. Hematological improvement re-
sponse was based on International Working Group (IWG)
2006 criteria [8,9].
Microarrays
Total RNA was purified from 5-10 ×106 mononuclear cells
using Trizol (Invitrogen) and analyzed for gene expression
on the Illumina HT12v4 whole genome array according to
the manufacturer’s protocol. RNA was available on 30
patients enrolled in the trial at the two institutions.
Gene marker analysis
The selection of genes associated with the responders (R)
vs. non-responders (NR) phenotype was obtained using a
normalized and rescaled mutual information (NMI) score.
This quantity was obtained using a kernel-density-based
estimate of the joint probability and the mutual informa-
tion distribution between the phenotype and each gene
profile. The resulting mutual information [10] was then
normalized by the joint-entropy in order to provide a more
universal metric [11], rescaled to the interval (0, 1), and
assigned a “directionality” sign defined according to the
sign of the Pearson correlation between the phenotype
and the gene profile. A perfect gene-phenotype match
(anti-match) using this NMI score corresponds to a +1
(−1) value, and a random match attains approximately 0.
This quantity as a metric for gene selection has advantages
over the Pearson correlation and other more traditional
two-sample tests, such as its increased sensitivity and
wider high-score dynamic range to detect nonlinear rela-
tionships, and its capability to match continuous or/and
discrete profiles and phenotypes. The significance of a
given NMI score is typically estimated by a permutation
test where the values of the phenotype are randomly per-
mutated many times, and a nominal p-value is computed
according to how many times the matching scores of the
random permutations are more extreme than the actual
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small, we opted for not performing the permutation test
and focused instead on analyzing the 100 genes with the
highest (50) and lowest (50) NMI scores.Gene set/pathway analysis
To project the gene profiles into the space of pathways,
we used a single-sample Gene Set Enrichment Analysis
(ssGSEA) [12-17]. The gene-expression values were first
rank-normalized and sorted independently, sample per
sample. Then a per-gene enrichment score for each gene
set/pathway was computed based on the integrated dif-
ference between the empirical cumulative distribution
functions of: i) the genes in the gene set vs. ii) the genes
not in the set. This procedure is similar to the computa-
tion of standard Gene Set Enrichment Analysis [13], but it
is based on absolute rather than differential expression.
The selection of gene sets/pathways more associated with
the responders vs. non-responders phenotype was obtained
using an NMI as was done with the gene profiles (see
above paragraph). The sources of gene sets/pathways were:
i) the C2 sub-collection of curated and functional gene sets
from the Molecular Signatures Database (MSigDB) release
2.5 (www.broadinstitute.org/msigdb); ii) an internal data-
base of signatures of oncogene activation containing over
300 gene sets defined from data generated in our labora-
tory, from GEO datasets, and from the biomedical litera-
ture; and iii) gene sets representing hematopoietic cell
populations [18]. We considered a total of 2776 gene sets.
The selection analysis was restricted to the 60 gene sets/
pathways with the 30 highest and 30 lowest NMI scores.Results and discussion
In order to identify an expression signature of ezatiostat
response, prior to therapy with the drug, the genome-wide
gene expression profiles of bone marrow aspirate mono-
nuclear cells were obtained from patients with MDS.
Samples of nine responders and 21 non-responders were
available for analysis. The nine responders included one
with a baseline single erythroid cytopenia, one with a
single platelet cytopenia, one with erythroid-neutrophil
cytopenias, two with erythroid-platelet cytopenias, two
with neutrophil-platelet cytopenias and two with triline-
age cytopenia (Table 1). The non-responders included
11 patients with a single erythroid cytopenia, one with
single platelet cytopenia, one with single netrophil cyto-
penia, two with erythroid-platelet cytopenias, two with
erythroid-neutrophil cytopenias, and one with trilineage
cytopenias. There were 18 patients with refractory anemia
(RA); eight with RA with ringed sideroblasts (RARS); three
with RA with excess blasts, type 1 (RAEB-1); and one with
RAEB-2. Patient samples had similar representation in both
the responder and the non-responder groups (Table 1).We compared the gene expression profiles of responders
and non-responders to identify genes that correlate with
ezatiostat response. The top 100 marker genes (50 under-
expressed and 50 over-expressed in the responders) were
identified using a sensitive metric based on the normal mu-
tual information (NMI; see Methods) (Figure 1A and B).
A majority of the top genes in both profiles are tran-
scripts of as-yet unknown function. Most notably, how-
ever, there are two microRNA (miR) genes that are
differentially expressed. Responders under-express miR-
129 and over-express miR-155. miRNAs are small non-
coding RNAs of 18–25 nucleotides that bind the 3’ UTR
of mRNA, resulting in suppressed translation or mRNA
degradation. This post-transcriptional control has been
found to be perturbed in a wide variety of tumors, where
it has been shown to have both oncogenic and tumor-
suppressor activities [19]. Surprisingly, both miRNAs
have been shown to mediate control of molecular path-
ways associated with the pathophysiology of MDS.
Reduced expression of miR-129 has been found in a
variety of primary solid tumors and has been shown to
reduce proliferation by targeting the G! S cell cycle
kinase CDK6 in lung epithelial-derived cells [20]. Inter-
estingly, one of the direct targets of miR-129 is the onco-
gene SOX4, a member of the SRY-related high mobility
group box family of transcription factors [21]. Over-
expression of SOX4 has been demonstrated in pros-
tate, liver, lung, bladder, and medulloblastoma cancers
exhibiting poor prognosis [21]. SOX4 has also been
shown to target growth factor receptors that when stimu-
lated increase proliferation as well as inhibit differentiation
via suppression of other transcription factors [22]. Sup-
porting the role of SOX4 in myeloid cells are the in vitro
studies showing that over-expression of SOX4 in 32D cells
resulted in the suppression of cytokine-induced granulo-
cyte differentiation [23]. Other predicted target genes are
components of the RISC complex that processes miRNAs
from their precursor molecules [22]. Thus the low expres-
sion of miR129 seen in responders would be expected to
aberrantly affect proliferation and differentiation and,
through dysregulated miRNA processing, to participate in
oncogenic transformation. These are precisely the path-
ways that are associated with the evolution of MDS.
In contrast, miR-155 is over-expressed in patients who
responded to ezatiostat. miR-155 has been previously
shown to be over-expressed in bone marrow cells of
patients with acute myelogenous leukemia (AML) [24].
Recently, c-MYB was shown to bind to the promoter re-
gion of the gene for miR-155 and to stimulate its tran-
scription in B-cell chronic lymphocytic leukemia [25]. It
may be that in MDS as well, MYB stimulates expression of
miR155. This observation is especially important in light
of recent studies that showed that forced expression of
miR-155 in mouse hematopoietic marrow cells results
Table 1 Myelodysplastic syndrome disease characteristics of patients treated with ezatiostat and analyzed by Illumina
expression arrays
Baseline
Cytopenia
Illumina
#
Response Sex Age Hgb WBC ANC Platelets WHO IPSS Blasts
(%)
Karyotype
E only TLK-1 NR F 69 9.3 4.4 3.08 325 RARS Int-1 1 46,XX,del(11)(q14q23)[11]/46,XX[9]
E only TLK-10 NR F 84 7.7 3.7 2.07 324 RAEB-
2
Int-1 10 NA
E only TLK-11 NR M 53 11 9.7 7,00 310 RA Int-1 2 47,XY[19]
E only TLK-12 NR M 81 8.9 4..1 2.10 343 RA Low 1 45,X,-Y[4]/46,XY[16]
EN TLK-13 NR F 72 10 1.6 0.58 113 RAEB-
1
Int-1 6 46,XX[19]
P only TLK-14 NR M 76 12 1.7 1.27 94 RA Low 1 45,X,-Y[19]
E only TLK-15 NR F 67 6.2 1.8 1.08 133 RA Low 3-5 46,XX[19]
NP TLK-16 NR F 68 12.2 3.2 1.05 73 RA Low <5 46,XX[19]
EN TLK-2 NR M 67 10 2.8 1.232 120 RA Int-1 1 46,XY[20]
EP TLK-21 NR M 63 10 3.2 0.64 76 RA Int-1 <5 46,XY[19]
E only TLK-27 NR F 73 9.2 4.6 3.22 221 RARS Int-1 0-1 46,XX,der(7)t(1;7)(q25;36)
ort(1;7)(q23;q32)[5]/46,Xdel(X)(q24q28),
der(7)t(1;7)(q25;q36) ort(1;7)(q23;q32)[15]
N only TLK-28 NR M 67 14 3.2 0.99 108 RARS NA NA 46,XY[19]
ENP TLK-29 NR F 74 10.8 3.7 1.27 56 RA Int-1 1 46,XX,dup(1)(q21q42)[16]/46,XX[4]
E only TLK-3 NR M 71 8.9 2.1 1.39 108 RA Low 0-1 46,XY[19]
EP TLK-30 NR M 79 10 3.17 3.36 101 RA Low 1 46,XY,del(20)(q11.2q13.3)[19]
P only TLK-4 NR M 77 13 3.3 2.25 93 RA Int-1 0 46,XY-20,+/der(20)del(20)(p12)del(20)
(q11.2)[21]
E only TLK-5 NR M 81 7.8 10.8 7.88 157 RARS Low 2 46,XY,del(2)(p13),inv(5)(q13q33),
add(13)(q22)[7]/46,XY,del(5)(q13q33)
[3],
/add(13)(q22)[3]/46,XY[10]
E only TLK-6 NR M 73 10 3.9 3 289 RA Low 1 46,XY[20]
E only TLK-7 NR F 67 11 8.3 3.74 251 RARS Int-1 1-2 47,XX,+8[14]/46,XX[6]
NP TLK-8 NR M 75 12 2.9 1.22 104 RA Int-1 1 44,XY,del(3)(p12p21),-5-9,
add(13)(p11.2)[5]/44,X,-Y,del(3)
(p12p21),
del(5)(q13q33),add (6)(q21),-9,-12,
add(13)(p11.2),+mar[2]/43,sdl118
[2]/43,sdl2,add(7)(q22)[6]/46,XY[5]
E only TLK-9 NR M 77 9.1 4 2.6 253 RARS Low 1 46,XY[19]
ENP TLK-17 R F 66 8.7 2 0.34 90 RARS Int1 3 46,XX[19]
E only TLK-18 R M 80 9.3 2.7 1.9 168 RA Low 4 46,XY[19]
ENP TLK-19 R M 79 10 3.3.. 0.79 98 RAEB-
1
Int-1 4 46,XY,t(2;3)(p15;q27)[11]/46,XY [9]
EN TLK-20 R M 68 9.7 2.8 0.67 336 RARS Low 2 46,XY[19]
P only TLK-22 R M 71 11 5.64 3.38 35 RA Low 1 46,XY[19]
NP TLK-23 R F 71 13 2.6 1.48 106 RA Int-1 0-1 46,XX,-9,del(11)(q13),+mar[22]/46,XX
[2]
EP TLK-24 R M 81 9.2 5.6 3.02 148 RA Low 1 45,X,-Y[11]/46,XY[9]
EP TLK-25 R M 79 11 3.7 1 68 RAEB-
1
Int-1 5 46,XY[19]
NP TLK-26 R F 75 13 3.6 1.26 39 RA Low 3 46,XX[19]
Abbreviations: ANC absolute neutrophil count, E erythroid, F female, Hgb hemoglobin, Int-1 International-1, IPSS International Prognostic Scoring System, M male, N
neutrophil, NR nonresponder, P platelet, R responder, RA refractory anemia, RAEB-1 refractory anemia with excess blasts type 1, RAEB-2 RA with excess blasts type
2, RARS refractory anemia with ringed sideroblasts, WBC white blood count, WHO World Health Organization.
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Figure 1 Patients who responded to ezatiostat under-expressed miR-129 (A) and over-expressed miR-155 (B).
Galili et al. Journal of Hematology & Oncology 2012, 5:20 Page 5 of 8
http://www.jhoonline.org/content/5/1/20in granulocyte/monocyte expansion, with these cells hav-
ing dysplastic features [24]. This proliferation was accom-
panied by decreased erythrocytes, megakaryocytes, and
lymphocytes in the marrow. In addition, when expression
analysis was performed on the marrow cells, genes known
to be important for normal hematopoiesis were found to
be down-regulated.Figure 2 Three pathways, mTOR, JAK2, and JNK, were under-expresseSingle-sample Gene Set Enrichment Analysis was per-
formed to find the most salient differences in terms of
pathways and biological processes between responders and
non-responders. Most notably, three pathways, mTOR,
JAK2 and JNK, were all found to be under-expressed in
the responders (Figure 2). All three have significant impli-
cations in the process of hematopoiesis.d in patients who responded to ezatiostat.
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tor of mTOR and functions as an antiapoptotic kinase.
AKT is the major downstream target of PI3K (phophoino-
sitide-3 kinase), which may be activated by receptor tyro-
sine kinases (RTKs), including epidermal growth factor
receptor (EGFR), insulin-like growth factor-1 receptor
(IGF-1R), and G protein-coupled receptors (GPCRs). It
has been shown that the PI3K/Akt/mTOR pathway is acti-
vated in high-risk MDS, when compared to lower risk or
healthy controls [26]. In addition, mTOR was specifically
shown to be upregulated in the myeloid progenitors of
high-risk MDS. These results suggest that this pathway
participates in the evolution of MDS and that patients with
low expression of these genes may respond to ezatiostat.
JAK2 (tyrosine Janus Kinase-2) is an important regulator
of erythropoiesis. When erythropoietin binds to its recep-
tor on progenitor cells, the receptor forms homodimers
that physically associate with JAK2, resulting in phosphor-
ylation and activation. The activated tyrosine residues then
associate with multiple downstream adaptors and effec-
tors, including PI3K and JNK [27,28]. The resulting effects
are promotion of erythroid differentiation and the synthe-
sis of hemoglobin. As with the mTOR pathway, those
patients able to respond to ezatiostat appear to be those
who under-express genes of the JAK2 activation pathway.Figure 3 The gene-set profile of JNK-inhibited keratinocytes is similarLastly, and most striking, was the finding that the JNK/
JUN pathway, which has been shown to be central to
ezatiostat’s molecular mechanism of action, is also under-
expressed in responding patients. This gene set, as defined
by the GEO dataset GDS2081, was derived from expres-
sion studies in primary cultured human epidermal kerati-
nocytes, with activated JNK/JUN exposed to the JNK
inhibitor drug SP600125 and analyzed on Affymetrix
HGU95Av2 arrays [29]. A heatmap of responders/
non-responders was derived from the combined enrich-
ment score of the top/bottom 200 genes, of which the top
expressing genes are shown in Figure 3. Most notably, the
gene-set profile of the JNK-inhibited keratinocytes is highly
similar to the gene-set profile of patients who respond to
ezatiostat. In other words, the profile is the same when the
JNK pathway is dysregulated in vitro by the drug or patho-
logically, as in some MDS patients. Ezatiostat has been
shown to activate the JNK/JUN pathway; thus it is reason-
able to expect that patients whose pre-treatment marrow
cells show low expression will respond to ezatiostat ther-
apy. In contrast, we show here that patients whose cells do
not under-express the JNK/JUN pathway are not likely to
benefit from additional activation by ezatiostat.
In conclusion, a bedside-to-bench strategy correlating
MDS patient pre-treatment genomic data with clinicalto the gene-set profile of patients who respond to ezatiostat.
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investigational drug’s clinical efficacy. These signature
genes and signaling pathways positively correlate with
the known mechanism of action of ezatiostat. The gen-
omic signature reported herein that distinguishes
responders from non-responders among MDS patients
treated with ezatiostat may enable the future selection
of patients who are most likely to positively benefit from
ezatiostat treatment. These markers could potentially be
developed into a clinical diagnostic test for MDS patient
sensitivity to ezatiostat treatment.
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